TB-500
Also known as: Thymosin Beta-4, Tβ4, Thymosin B4
TB-500 is a synthetic version of the naturally occurring peptide Thymosin Beta-4, which plays a crucial role in tissue repair, cell migration, and blood vessel formation in the body.
Key Findings at a Glance
- •TB-500 is one of the few peptides whose low molecular weight allows it to travel long distances through tissues and potentially affect injury sites far from the injection location.
- •A landmark Nature study showed TB-500 reduces heart attack damage by activating integrin-linked kinase, a survival pathway previously unconnected to healing peptides.
- •TB-500 works by sequestering G-actin monomers, effectively reprogramming cells to migrate toward wounds rather than simply dividing in place.
- •Research demonstrates TB-500 shifts macrophages from the inflammatory M1 type to the regenerative M2 type, accelerating the transition from damage control to tissue rebuilding.
TB-500 Overview & Molecular Profile
TB-500 is a synthetic analog of Thymosin Beta-4 (Tβ4), a 43-amino-acid peptide (C₂₁₂H₃₅₀N₅₆O₇₈S; CAS 77591-33-4) naturally present in virtually all nucleated cells and concentrated in wound fluid and platelets. TB-500 corresponds to the Tβ4 segment most responsible for actin binding and cellular migration. Extensive preclinical research has documented effects on wound healing, cardiac tissue repair, angiogenesis, and hair follicle stimulation—with a landmark 2004 Nature publication establishing its cardioprotective mechanism. No human clinical trials have been completed as of 2026.
Mechanism of Action: Gene Activation & Angiogenesis
TB-500 works primarily by upregulating actin, a cell-building protein that plays a crucial role in cell migration, division, and proliferation. The peptide promotes cell migration by forming a complex with actin, allowing cells to move to areas requiring repair. It also promotes angiogenesis and reduces inflammation. TB-500 has been shown to interact with HIF-1 alpha and VEGF pathways, promoting new blood vessel formation in damaged tissues.
Research-Observed Effects
Enhanced Cell Migration
Research demonstrates TB-500's critical role in promoting cell migration to injury sites through direct interaction with G-actin, facilitating actin polymerization and cytoskeletal reorganization essential for cell motility. The peptide has been shown to promote migration of endothelial cells, keratinocytes, and various stem cell populations toward damaged tissue areas. Studies document TB-500's ability to increase cell migration speed and directional persistence through modulation of integrin-linked kinase (ILK) signaling pathways. This enhanced cellular mobility is fundamental to wound healing processes, tissue regeneration after injury, and vascular repair mechanisms. Research indicates TB-500's unique low molecular weight allows it to travel through tissues more effectively than many other healing factors, potentially affecting distant injury sites.
Wound Healing Promotion
Extensive studies demonstrate TB-500's multi-faceted approach to wound healing including promotion of angiogenesis for improved blood supply to healing tissues, enhanced keratinocyte differentiation for skin regeneration, and acceleration of collagen matrix deposition for structural tissue repair. Research in dermal wound models shows significantly faster wound closure times, improved wound contraction, and superior cosmetic outcomes with reduced scarring. The peptide promotes formation of new blood vessels through upregulation of VEGF (vascular endothelial growth factor) and interaction with HIF-1 alpha pathways. Studies in chronic wound models including diabetic ulcers and pressure sores demonstrate enhanced healing even in compromised tissue environments. TB-500 has been investigated for burn wound treatment applications, surgical incision healing, and traumatic wound recovery.
Cardiac Tissue Repair
Groundbreaking research published in Nature and other high-impact journals demonstrates TB-500's significant potential for cardiac tissue regeneration following myocardial infarction (heart attack). Studies show the peptide promotes cardiac muscle cell survival, reduces scar formation in damaged heart tissue, and may stimulate cardiomyocyte regeneration from progenitor cells. Research indicates TB-500 activates integrin-linked kinase in cardiac cells, promoting survival signaling and reducing apoptosis after ischemic injury. Animal studies have documented improved cardiac function, reduced infarct size, and enhanced left ventricular ejection fraction following treatment. The peptide has been investigated for applications in coronary artery disease research, heart failure mechanisms, and post-heart attack recovery optimization strategies.
Hair Follicle Stimulation
Preliminary research suggests TB-500 may promote hair follicle stem cell activation, migration, and differentiation through its effects on cell motility and tissue regeneration pathways. Studies indicate the peptide may enhance blood supply to hair follicles through angiogenic mechanisms, potentially improving nutrient delivery to growing hair. Research in animal models has documented increased hair density, accelerated hair regrowth after shaving, and improved follicle health in treated subjects. The peptide's effects on keratinocyte migration and epithelial cell function may contribute to hair shaft formation and quality. These findings have generated interest in TB-500 for androgenetic alopecia (male and female pattern baldness) research, alopecia areata mechanisms, and chemotherapy-induced hair loss recovery studies.
Anti-inflammatory Properties
Research demonstrates TB-500's significant anti-inflammatory effects through reduction of pro-inflammatory cytokine expression including IL-1 beta, TNF-alpha, and various chemokines involved in inflammatory cell recruitment. The peptide has been shown to reduce oxidative stress markers and reactive oxygen species production in damaged tissues, creating a more favorable environment for regeneration. Studies indicate TB-500 may modulate macrophage polarization from pro-inflammatory M1 to pro-regenerative M2 phenotypes, enhancing the transition from inflammatory to healing phases. Research in models of inflammatory conditions including colitis, arthritis, and dermatitis shows reduced tissue damage and accelerated resolution of inflammation. These anti-inflammatory properties appear synergistic with tissue repair mechanisms, contributing to faster overall recovery in injury models.
Pharmacokinetics
Plasma Concentration Profile (TB-500 Pharmacokinetics)
Figure: Relative plasma concentration profiles comparing IV (rapid distribution) and SC (gradual absorption with T1/2 of approximately 110 min) administration routes for TB-500.
Research Dosing Information
| Route | Dose | Frequency | Notes |
|---|---|---|---|
| Subcutaneous | 0.1–2.0 mg | 1–2× per week | Most common interval in repair studies |
| Intramuscular | 0.1–2.0 mg | 1–2× per week | Cardiac and musculoskeletal models |
| Intravenous | 0.1–1.0 mg/kg | As per protocol | Used in cardiac ischemia models |
Note: Dosing information is provided for research reference only and is based on published studies using research subjects. This is not a recommendation for any use.
Research Studies & References
Thymosin beta4 promotes dermal healing
Malinda KM, Sidhu GS, et al. (1999). Journal of Investigative Dermatology
This seminal study established TB-500's role in dermal wound healing through a series of in vitro and in vivo experiments examining keratinocyte and endothelial cell behavior. Researchers demonstrated that Thymosin Beta-4 significantly accelerates wound closure in animal models while simultaneously promoting keratinocyte migration and endothelial cell tubule formation. The study revealed that TB-500 treatment increased cell migration rates by 42% in keratinocyte scratch assays and enhanced angiogenesis in wound beds. Histological analysis showed improved collagen organization and reduced scar tissue formation in treated wounds. These findings established the foundation for subsequent research into TB-500's therapeutic potential for chronic wounds, burn injuries, and post-surgical healing optimization.
Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration
Bock-Marquette I, Saxena A, et al. (2004). Nature
This landmark Nature publication transformed understanding of TB-500's cardioprotective mechanisms by identifying integrin-linked kinase (ILK) as a key mediator of its cardiac effects. The study demonstrated that TB-500 administration following experimental myocardial infarction significantly reduced infarct size and improved cardiac function in mouse models. Researchers showed that the peptide promotes cardiac progenitor cell migration to damaged areas while simultaneously protecting existing cardiomyocytes from apoptosis through Akt/protein kinase B signaling activation. The study documented improved left ventricular function, reduced fibrosis, and enhanced neovascularization in treated animals. These groundbreaking findings positioned TB-500 as a promising candidate for cardiac regeneration research and opened new avenues for investigating heart attack recovery and heart failure treatment mechanisms.
Thymosin beta 4 promotes angiogenesis, wound healing, and hair follicle development
Philp D, Nguyen M, et al. (2007). Annals of the New York Academy of Sciences
This comprehensive study examined TB-500's multi-tissue effects on angiogenesis, wound healing, and hair follicle biology across multiple experimental models. Researchers documented enhanced blood vessel formation through VEGF pathway activation, accelerated wound closure in both acute and chronic wound models, and stimulation of hair follicle stem cell migration and differentiation. The study demonstrated that TB-500 promotes endothelial cell differentiation and tubule formation in vitro while enhancing hair shaft elongation and follicle cycling in vivo. Analysis revealed the peptide's effects on stem cell mobilization and tissue-specific progenitor cell activation. These findings established TB-500 as a multifunctional regenerative peptide with applications spanning dermatology, cardiovascular research, and hair loss treatment investigations.
Comparative Research
Explore in-depth research analyses and comparative studies featuring TB-500.
Frequently Asked Questions
What is TB-500 and how does it relate to Thymosin Beta-4?
TB-500 is a synthetic peptide corresponding to a key fragment of Thymosin Beta-4 (Tβ4), a 43-amino-acid protein naturally present in nearly all nucleated cells. TB-500 contains the actin-binding domain of Tβ4 that drives the peptide's effects on cell migration and wound healing. The full Tβ4 protein is not easily synthesized at research scale, so TB-500 serves as a tractable analog for preclinical investigations. The terms TB-500 and Thymosin Beta-4 are sometimes used interchangeably in the research community, though they refer to different molecules.
How does TB-500 promote tissue repair at the molecular level?
TB-500's primary mechanism is sequestration of G-actin monomers—the building blocks of actin filaments. By binding to free G-actin, TB-500 modulates actin polymerization dynamics, which directly enables cell migration toward injury sites. Additionally, TB-500 activates integrin-linked kinase (ILK), promoting cell survival signaling via the Akt pathway. It also upregulates VEGF and interacts with HIF-1α to stimulate new blood vessel formation (angiogenesis). Together, these mechanisms coordinate the cellular migration, survival, and vascularization phases of tissue repair.
What is TB-500's cardioprotective mechanism?
A landmark 2004 Nature study (PMID: 15496926) established that TB-500 activates integrin-linked kinase (ILK) in cardiac cells, which triggers downstream pro-survival signaling including Akt phosphorylation. In mouse myocardial infarction models, TB-500 reduced infarct size, decreased fibrosis, and improved left ventricular ejection fraction. It also promoted migration of cardiac progenitor cells toward damaged myocardium. This cardioprotective effect was demonstrated in mice that already had established infarction—not just as a preventive measure.
Why can TB-500 affect injury sites far from the injection point?
TB-500's relatively low molecular weight and structural properties allow it to diffuse extensively through connective tissue and cross tissue planes more readily than larger proteins. Research has documented responses at anatomical sites distant from the injection location. This systemic distribution property distinguishes TB-500 from growth factors that typically act locally at the site of application. The mechanism of long-distance transport is hypothesized to involve vascular distribution combined with extracellular matrix diffusion.
What animal studies support TB-500's wound healing effects?
A foundational 1999 study (PMID: 10233741) demonstrated Thymosin Beta-4 increases keratinocyte migration by 42% in scratch assays and enhances angiogenesis in wound beds. Subsequent studies showed improved wound closure, collagen organization, and reduced scarring. Research in cardiac models (Nature, 2004) showed significant infarct size reduction. Hair follicle studies documented increased density and accelerated regrowth. All of this evidence comes from animal or cell culture models; human clinical trials have not been published.
How does TB-500 differ from BPC-157?
Both are widely studied repair peptides, but they operate through distinct mechanisms. TB-500 primarily works through actin-binding and ILK activation to promote cell migration and cardiac protection. BPC-157 works through the nitric oxide system, Egr-1/NAB2 angiogenesis regulation, and growth hormone receptor upregulation in fibroblasts. TB-500 has stronger evidence for cardiac tissue specifically, while BPC-157 has more extensive gastrointestinal research. BPC-157 has the unique property of oral bioavailability due to its gastric stability; TB-500 does not share this characteristic.
What is TB4-Frag and how does it compare to TB-500?
TB4-Frag (also called TB4-Frag or Tβ4 Fragment) is a shorter peptide derived from the same Thymosin Beta-4 sequence as TB-500. It represents a smaller segment of the protein and has distinct pharmacokinetics compared to TB-500. The shorter fragment may have different tissue distribution and duration of action. Research on TB4-Frag is less extensive than on TB-500, and direct head-to-head pharmacological comparisons are limited in the published literature.
Has TB-500 been tested in any human studies?
As of early 2026, no peer-reviewed human clinical trials for TB-500 specifically have been published. The cardiac research with Thymosin Beta-4 that entered Phase I/II human trials used the full protein (Tβ4), not the TB-500 fragment—and those trials were largely discontinued before completion. The preclinical evidence for TB-500 is substantial (including a landmark Nature paper), but translation to human data is not yet established. TB-500 is not approved for human use by any regulatory agency.
BPC-157
C62H98N16O22
BPC-157 is a synthetic pentadecapeptide derived from a protective protein found in gastric juice. It has been extensively studied for its potential regenerative and protective properties in various tissue types.
GHK-Cu
C14H23CuN6O4
GHK-Cu is a naturally occurring copper complex of the tripeptide glycyl-L-histidyl-L-lysine. It has been extensively studied for wound healing, skin rejuvenation, and tissue remodeling.